Ultimately, it can be concluded that engineering CAR-Ts for the secretion of IL-7 and CCL19 could have a therapeutic advantage against solid tumors by increasing the tumor-homing capacity of CAR-Ts; however, in the context of ovarian cancer, clinical investigations with large patient populations must be conducted for more elucidation (151). Here, IL7 is linked to ovarian cancer.